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A disintegrin and metalloproteinase 10 (ADAM10), a disintegrin and metalloproteinase that resides in the 
postsynaptic densities (PSDs) of excitatory synapses, has previously been shown to limit β-amyloid peptide 
(Aβ) formation in Alzheimer’s disease (AD). ADAM10 also plays a critical role in regulating functional mem-
brane proteins at the synapse. Using human hippocampal homogenates, we found that ADAM10 removal 
from the plasma membrane was mediated by clathrin-dependent endocytosis. Additionally, we identified 
the clathrin adaptor AP2 as an interacting partner of a previously uncharacterized atypical binding motif in 
the ADAM10 C-terminal domain. This domain was required for ADAM10 endocytosis and modulation of its 
plasma membrane levels. We found that the ADAM10/AP2 association was increased in the hippocampi of 
AD patients compared with healthy controls. Long-term potentiation (LTP) in hippocampal neuronal cultures 
induced ADAM10 endocytosis through AP2 association and decreased surface ADAM10 levels and activity. 
Conversely, long-term depression (LTD) promoted ADAM10 synaptic membrane insertion and stimulated its 
activity. ADAM10 interaction with the synapse-associated protein-97 (SAP97) was necessary for LTD-induced 
ADAM10 trafficking and required for LTD maintenance and LTD-induced changes in spine morphogenesis. 
These data identify and characterize a mechanism controlling ADAM10 localization and activity at excitatory 
synapses that is relevant to AD pathogenesis.
Introduction
Alzheimer’s disease (AD) is the most common cause of dementia, 
and at present, therapeutic options to cure the disease are scarce. 
The underlying neuropathology of AD includes extracellular depo-
sition of β-amyloid peptide (Aβ) and intraneuronal accumulation 
of aberrant forms of hyperphosphorylated tau as well as synapse 
dysfunction and neurodegeneration (1–3).
Substantial data indicate accumulation of Aβ in the brain, par-
ticularly in its nonfibrillar soluble oligomeric forms, as the prima-
ry influence driving synaptic dysfunction and a complex cascade 
of molecular events leading to dementia (4, 5).
Aβ derives from the concerted action of β-site APP-cleaving 
enzyme (BACE) (6), which cleaves the amyloid precursor protein 
(APP) at the Aβ N-terminus, and γ-secretase, which is respon-
sible for the cleavage of the APP C-terminal stub (7). On the 
other hand, APP can be alternatively processed by a disintegrin 
and metalloproteinase 10 (ADAM10) pathway that prevents the 
formation of toxic Aβ (8, 9). These 2 processes are differentially 
segregated within the cells: ADAM10 activity is localized in the 
trans-Golgi network or at the plasma membrane (9, 10), whereas 
BACE activity is mainly confined to the ER and to the endo-
somal/lysosomal system (11). Hence, understanding the mecha-
nisms that regulate the intracellular localization and traffick-
ing to the neuronal membrane of APP and the related secretases 
is central for the comprehension of AD pathogenesis and for 
devising rationale therapeutic approaches.
ADAM10 is an integral component of postsynaptic densities 
(PSDs) of excitatory synapses (12–14) and binds to synapse-associ-
ated protein-97 (SAP97), a member of the MAGUK family of pro-
tein scaffolds that governs the trafficking and synaptic anchoring 
of AMPA- and NMDA-type glutamate receptors. The interaction 
involves the SH3 domain of SAP97 and an atypical proline-rich 
domain within the C-terminal region of ADAM10, and favours 
the forward trafficking of ADAM10 and its localization in syn-
aptic membranes and, thereby, its APP-cleaving activity (12). The 
ADAM10/SAP97 interaction has been shown to be reduced in 
brains from AD patients (15), and the disruption of the association 
between SAP97 and ADAM10 in vivo using peptides leads to the 
generation of a nontransgenic model of the disease (16). Thus, for-
ward trafficking and membrane insertion are crucial not only for 
maintaining a pool of ADAM10 at synaptic sites and for ADAM10-
shedding activity, but also for healthy neuronal function.
Endocytosis represents another major pathway for controlling the 
abundance of synaptic proteins (17), and perturbations of clathrin-
mediated endocytosis proteins have been reported in numerous 
human disorders (18). Dendritic spines appear to contain core 
components of the endocytic machinery (clathrin, AP2, dynamin-2) 
at endocytic zones located laterally to PSDs (19, 20), and clathrin-
mediated endocytosis has been shown to modulate synaptic plastici-
ty; for example, it is required for downregulation of AMPA receptors 
and expression of long-term depression (LTD) (21, 22).
The relevance of clathrin-mediated endocytosis in AD has been 
recently highlighted by genome-wide association studies (GWAS), 
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which identified novel loci with significant association to AD (23–25). 
One of the genes identified is PICALM, an adaptor protein that 
binds clathrin, phoshoinositol, and the clathrin adaptor protein 
AP2 to aid the formation of clathrin-coated pits (23). Here, we 
demonstrate that ADAM10 binds directly to the clathrin adaptor 
protein AP2 and that this association is instrumental for enzyme 
internalization, is altered in hippocampi of patients affected by AD, 
and is regulated by activity-dependent plasticity processes.
Results
ADAM10 binds to the clathrin adaptor AP2, and this interaction is altered 
in AD patients. Clathrin-coated pit initiation is triggered by the 
recruitment of the clathrin adaptor AP2 to cargo proteins in the 
plasma membrane that can be mediated via direct binding of AP2 
to endocytic motifs within cytoplasmic domains of the target 
proteins (18). To address the role of endocytosis in regulating the 
membrane levels of ADAM10 and its potential relevance in the eti-
ology of AD (26, 27), we first verified whether the AP2 complex 
subunits bind ADAM10 in homogenate 
from human hippocampus. AP2 exists as 
a heterotetrameric assembly of 2 large sub-
units (α and β2), a medium subunit termed 
μ2, and a small subunit, σ (28).
Co-IP experiments using an anti-
ADAM10 antibody showed that α-adaptin, 
β2-adaptin, and μ2 subunits coprecipitate 
with ADAM10 (Figure 1A). The interaction 
was specific, as demonstrated by the obser-
vation that γ-adaptin, a subunit of AP1 com-
plex, did not bind to ADAM10 (Figure 1A).
We then searched for a possible alteration 
of the ADAM10/AP2 complex interaction in 
hippocampi from AD patients at Braak level 
4 (29) and from age-matched healthy con-
trols (HC). Total homogenates from hippo-
campi of HC and AD patients were IP with 
anti-ADAM10 antibody, and co-IP with AP2 
subunits was evaluated. A large increase 
in the amount of AP2 subunits bound to 
ADAM10 was observed in AD patients com-
pared with HC (Figure 1, B and C; α-adaptin: 
HC = 198.8 ± 55.8, AD = 412.5 ± 57.1, 
P = 0.023; β2-adaptin: HC = 227 ± 25.7, 
AD = 338.3 ± 39.5, P = 0.039; μ2: HC = 167.8 ± 
21.5, AD = 274.8 ± 38.9, P = 0.037; AD ver-
sus HC). As previously demonstrated, the 
ADAM10 total levels were not affected by 
the group (15), and no differences were 
detected between HC and AD patients in 
α-adaptin, β2-adaptin, and μ2 subunit lev-
els in total homogenates, suggesting that 
the increased association is not related to 
the augmented abundance of the partners 
(Figure 1, B and D; α-adaptin: HC = 71.5 ± 7.8, 
AD = 81.7 ± 7; β2-adaptin: HC = 67.3 ± 9.1, 
AD = 89.5 ± 9.5; μ2: HC = 52.3 ± 3, AD = 52.8 ± 
3.3; P > 0.05; AD versus HC). Moreover, 
we confirmed that γ-adaptin does not pre-
cipitate with ADAM10 in both HC and AD 
patients’ hippocampus homogenate and its 
expression is not affected by the group (γ-adaptin: HC = 21.7 ± 3.1, 
AD = 20.8 ± 4.9; P > 0.05; AD versus HC).
These data indicate AP2 as a new partner of ADAM10 and reveal 
a further alteration of ADAM10-binding capability in AD patients. 
In addition to the reported reduction of ADAM10/SAP97 associa-
tion (15), we show that the interaction of ADAM10 with AP2 is 
enhanced in hippocampus at early phases of sporadic AD.
The clathrin-adaptor protein complex AP2 binds an atypical binding 
motif in ADAM10 tail. To identify the domain of ADAM10 responsi-
ble for the interaction with AP2, we studied the complex in mouse 
brain. First, we confirmed the presence of ADAM10/AP2 complex 
by co-IP assays from total mouse brain homogenate. As shown in 
Figure 2A, the AP2 subunits, i.e., α-adaptin, β2-adaptin, and μ2 
subunit, coprecipitate with ADAM10.
To test the role of the cytoplasmic tail (Ct) of ADAM10 in the 
interaction and identify potential motifs recognizing AP2, we 
carried out pulldown assays where fusion proteins of glutathi-
one-S-transferase (GST) and GST bound to ADAM10 Ct (GST-
Figure 1
ADAM10 interacts with the clathrin adaptor AP2, and this association is increased in AD patients’ 
hippocampus. (A) Human hippocampus homogenate IP with a rabbit anti-ADAM10 antibody. WB 
analysis revealed the presence of AP2 subunits, α-adaptin, β2-adaptin, and μ2 subunit, but not 
of the AP1 subunit γ-adaptin, in the immunocomplex. IP ADAM10 was detected by WB with a rat 
anti-ADAM10 antibody. As shown in the right lanes, no signal is detectable when the sample is 
precipitated without ADAM10 antibody. Lanes were run on the same gel but were not contiguous. 
(B) Homogenates from hippocampi of 6 HC and 6 AD patients were IP with anti-ADAM10 anti-
body and AP2 subunits coprecipitation evaluated. ADAM10/AP2 association is increased in AD 
compared with HC. γ-adaptin does not precipitate with ADAM10 in both groups. The levels of IP 
ADAM10 were detected by WB with a rat anti-ADAM10 antibody. Left lanes show WB performed 
on total homogenate from HC and AD hippocampi. No alterations of α-adaptin, β2-adaptin, μ2 
subunit, γ-adaptin, and ADAM10 levels were detected. (C) OD was measured. Quantification of 
IP experiments in B (*P < 0.05, AD versus HC [C], n = 12). (D) Quantification of total levels of 
α-adaptin, β2-adaptin, μ2 subunit, shown in B (P < 0.05, AD versus HC, n = 12). All data were 
normalized on tubulin OD. In this and all subsequent figures, data represent mean ± SEM.
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Figure 2
AP2 interacts with 735RQR737 motif of ADAM10 tail. (A) Mouse brain homogenate was IP with ADAM10 antibody. AP2 subunits coprecipitate with 
ADAM10. IP ADAM10 was detected by WB. No signal is detectable when the sample is precipitated without ADAM10 antibody. (B) Pulldown 
assays performed with GST-ADAM10 Ct and GST from mouse brain homogenate. α-adaptin and μ2, but not γ-adaptin and ε-adaptin, are pre-
cipitated by ADAM10 Ct. (C) aa sequences of ADAM10 Ct deletion mutants (747Δ, 741Δ, 737Δ, 734Δ, 721Δ). (D) Pulldown assays performed 
with GST-ADAM10 Ct, 734Δ, and 721Δ mutants. Deletion of the last 15 aa abolishes AP2 subunit binding, whereas SAP97 interacts with the 
membrane proximal 27 aa of ADAM10 tail. (E) Pulldown assays carried out with all deletion mutants. The 735RQR737 motif is necessary for 
α-adaptin precipitation. (F) Pulldown assays performed with GST-ADAM10 Ct bearing mutations of 735RQR737 motif. No change in α-adaptin 
binding was detected. (G) Pulldown assays performed with GST-ADAM10 Ct mutated 735RQR737 to AQA. The mutation of both arginine residues 
to alanine abolishes α-adaptin binding, but does not affect SAP97 association. (H) Representative images of ADAM10 membrane staining 
(red) and α-adaptin (green) of COS7 cells expressing ADAM10 WT or ADAM10 AQA. Merged images are shown on the right. Scale bar: 20 μm. 
(I) Quantification of ADAM10 WT/α-adaptin and ADAM10 AQA/α-adaptin colocalization of experiments in H (*P < 0.05, ADAM10 WT versus 
ADAM10 AQA, n = 2 experiments, 12 cells per condition). In A and E–G, lanes were run on the same gel but were not contiguous.
Downloaded on June 12, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/65401
research article
2526 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 6   June 2013
Figure 3
ADAM10/AP2 interaction is relevant for ADAM10 endocytosis and membrane expression. (A) Antibody uptake assays were performed on COS7 cells 
transfected with either TacADAM10-RAR or the mutant TacADAM10-RAR AQA (lacking AP2-binding motif) or the deletion mutant Tac721Δ. TacAD-
AM10-RAR internalization was also analyzed after treatment with dynamin inhibitor dynasore (TacADAM10-RAR+dynasore, 80 μM for 30 minutes 
before the internalization assay). Representative images of cells returned to 37°C to allow endocytosis. A decrease in the number of internalization 
puncta of TacADAM10-RAR AQA and of the deletion mutant Tac721Δ, of TacADAM10-RAR+dynasore is detected when compared with TacADAM10-
RAR. Scale bar: 20 μm. (B) Quantification of the internalization index of experiments in A (*P < 0.05, TacADAM10-RAR AQA versus TacADAM10-RAR, 
Tac721Δ versus TacADAM10-RAR, TacADAM10-RAR+dynasore versus TacADAM10-RAR, n = 3 experiments, 27 cells per condition). (C) ADAM10 
WT and the mutant ADAM10 AQA, lacking the AP2-binding motif, were transfected into COS7 cells and surface/total labeling was analyzed. ADAM10 
WT was faintly localized at the surface despite intense intracellular labeling. In contrast, the mutant tested displayed strong surface staining. Scale bar: 
20 μm. (D) Quantification of surface expression ratios in C (*P < 0.05, ADAM10 WT versus ADAM10 AQA, n = 18–20 cells per condition).
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ADAM10 Ct) were incubated with mouse brain homogenate. GST-
ADAM10 Ct pulled down both the α-adaptin and μ2 subunits, 
demonstrating that the ADAM10 Ct binds the AP2 complexes 
(Figure 2B). The interaction was specific because other AP sub-
units, such as γ-adaptin and ε-adaptin, that compose AP1 and AP4 
complexes, did not bind to GST-ADAM10 Ct (Figure 2B).
To define the ADAM10 Ct sequence determinants required for its 
interaction with the AP2 complexes, we tested a series of deletion 
mutants of GST-ADAM10 Ct (Figure 2C). Truncation of up to the last 
15 aa of ADAM10 tail (GST-734Δ) completely abolished binding to 
both the α-adaptin and μ2 subunits of the AP2 complex (Figure 2D), 
indicating that this aa segment is required for ADAM10/AP2 inter-
action. In contrast, ADAM10 interaction with SAP97 (12) was pre-
served after deletion of either the last 15 aa (GST-734Δ) or the last 
28 aa, including the second proline-rich domain (GST-721Δ) of the 
ADAM10 tail (Figure 2D). These data demonstrate that our deletion 
mutants are functional and that the interaction domains responsible 
for SAP97 and AP2 do not overlap; a distal 15 aa sequence is respon-
sible for the binding to AP2 complex, while SAP97 interacts with 
the most membrane-proximal proline-rich domain and the second 
proline stretch is dispensable. AP2 complexes often bind to short, 
canonical peptide motifs on transmembrane cargo: Yxxφ motifs (30) 
or “dileucine” (D/ExxxLL) motifs (31). Other cargo-bearing non-
canonical sorting motifs, such as aa stretches enriched in arginine 
residues, may also bind to AP2 (32–34). The identified 15-aa region 
contains both a tyrosine residue and several arginines.
To narrow down the region responsible for AP2 binding, we 
performed pulldown assays with sequential deletion mutants of 
the last 15 aa of the ADAM10 tail. As shown in Figure 2E, while 
neither the removal of the last 2 arginines (747Δ) nor of the tyro-
sine residue (741Δ) affected α-adaptin precipitation, removing the 
735RQR737 motif prevented AP2 binding (734Δ). Single mutations 
of this motif did not compromise the interaction with α-adaptin, 
as demonstrated by pulldown assays (Figure 2F) but when both 
the 735R and 737R residues were mutated to alanine in the GST-
ADAM10 Ct fusion protein, the binding to α-adaptin was com-
pletely abolished (Figure 2G). Furthermore, SAP97 binding to 
GST-ADAM10 Ct fusion protein was not affected by the mutation 
of 735R and 737R residues to alanine, suggesting that SAP97 and 
AP2 do not compete for the binding to ADAM10 Ct (Figure 2G).
To confirm the pulldown assays’ results, we mutated 735R and 737R 
residues in the context of the ADAM10 full-length protein and com-
pared its colocalization with α-adaptin with that of ADAM10 WT. 
Because binding to endocytic motifs and AP2 recruitment occur at 
the plasma membrane, we measured the colocalization degree of 
α-adaptin and membrane-inserted ADAM10, which was detected in 
Figure 4
Structural characterization of ADAM10/AP2 binding. (A) ADAM10 sequence involved in binding the AP2 complex and its alignment with the most 
similar peptide sequence found in the PDB (Id: 1QWE) (B) Ribbon representation of the 1QWE peptide structure (PDB). Conserved aa are shown 
as red sticks with their backbone in orange. (C) Representation of the peptide–c-Src SH3 complex. The c-Src SH3 domain is represented in light 
gray ribbon and the interacting residues in gray stick. The interactions established by the 2 molecular partners are highlighted by dashed lines. 
(D) List of the interactions between the peptide and the c-Src SH3 domain. (E) Structural superposition between the residues of the c-Src SH3 
domain and the β2 subunit of the AP2 complex colored in gray and black, respectively. The same color code in B was used for the peptide. (F) 
Ribbon representation of the structures of the c-Src SH3 domain and a portion of the β2 subunit of the AP2 complex, reported in light and dark 
gray, respectively. The interacting residues and the peptide are also shown.
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Figure 5
LTP enhances ADAM10/AP2 association and ADAM10 internalization. Schematic representation of the chemical protocol used to induce cLTD 
(A) and cLTP (B). (C) ADAM10/SAP97 and ADAM10/AP2 co-IP assays performed on homogenates of control and either cLTD or cLTP-treated 
neurons. cLTD increases ADAM10/SAP97 coprecipitation, while cLTP enhances ADAM10/AP2 complex. (D) Quantification of OD of experiments 
in C (*P < 0.05 cLTP versus C, n = 6, cLTD versus C, n = 4). (E) LTP/LTD were induced by electrophysiological stimulation in hippocampal slices. 
ADAM10/SAP97 and ADAM10/AP2 co-IP assays were performed in CA1 homogenates. LTD fosters ADAM10/SAP97 association without affect-
ing ADAM10/α-adaptin and ADAM10/μ2 precipitation. LTP stimulates ADAM10 association to both α-adaptin and μ2, while it does not change 
ADAM10/SAP97 complex levels. (F) Quantification of OD of experiments in E (*P < 0.05 LTP versus C, LTD versus C, n = 4). (G) ADAM10 (green) 
and α-adaptin (red) staining in dendritic compartment after either cLTD or cLTP induction in hippocampal neurons. Merged images are shown on 
the right. Scale bar: 4 μm. (H) Quantification of ADAM10/α-adaptin colocalization of experiments in G (*P < 0.05 cLTP versus C, n = 2 experiments, 
10 neurons per condition). (I) Internalization assays were performed on neurons expressing TacADAM10-RAR either exposed or not exposed to 
cLTP treatment. Representative images of surface (green) and internalized (red) TacADAM10-RAR from control and cLTP induced neurons are 
shown. Insets show higher magnification examples of internalized puncta in dendrites. Scale bars: 20 μm; 4 μm (insets). (J) Quantification of the 
internalization index of experiments in I (*P < 0.05 cLTP versus C, n = 2 experiments, 10 neurons per condition).
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nonpermeabilizing conditions with an antibody against ADAM10 
extracellular domain. We found a significant decrease in the colocal-
ization of the ADAM10 AQA mutant when compared with ADAM10 
WT (Figure 2, H and I; ADAM10 WT = 21.4% ± 4.2%, ADAM10 
AQA = 5% ± 1.1%; P = 0.001, ADAM10 AQA versus ADAM10 WT). 
Together, these experiments identified a previously uncharacterized 
atypical AP2-binding motif within the ADAM10 Ct.
The clathrin-adaptor protein complex AP2 is responsible for ADAM10 inter-
nalization. To evaluate the functional significance of the 735RQR737 
AP2-binding motif in ADAM10 endocytosis, we performed fluores-
cence-based “antibody feeding” assays to assess internalization in 
COS7 cells expressing TacADAM10-RAR, a chimera of the surface 
reporter protein Tac (human IL-2 receptor α-subunit) (35) with a 
modified version of the ADAM10 C-terminal tail. The modification 
consisted in a mutation in the ER retention motif in ADAM10 that 
allowed its ER exit and permitted delivery to the surface (36). COS7 
cells were transfected with either the chimera TacADAM10-RAR-
AQA, able to exit the ER and carrying the mutated AP2 binding motif, 
or the deletion mutant TacADAM10 721Δ, which lacks the last 28 aa.
Surface TacADAM10 chimeras were first “pulse labeled” in 
live cells, at 4°C to block membrane trafficking by incubation 
with anti-Tac antibody. Subsequently, cells were either returned 
to 37°C to resume endocytosis or kept at 4°C as control. The 
accumulation of antibody-bound TacADAM10 chimeras in 
intracellular compartments and the amount of antibody-bound 
TacADAM10 chimeras remaining on the surface were tracked by 
quantitative immunofluorescence staining under permeabilizing 
versus nonpermeabilizing conditions. The ratio of intracellular 
fluorescence/surface fluorescence (internalization index) was 
used to control for the variable expression levels of TacADAM10 
chimeras in different cells.
We found that the internalization indexes of both TacADAM10-
RAR-AQA and TacADAM10 721Δ were significantly lower com-
pared with TacADAM10-RAR (Figure 3, A and B; internalization 
index, TacADAM10-RAR-AQA = –21.7% ± 2.9%, TacADAM10 
721Δ = –18.2% ± 3.9%; P < 0.05, TacADAM10-RAR versus TacAD-
AM10-RAR-AQA, TacADAM10 721Δ), demonstrating that the 
AP2-binding motif 735RQR737 is responsible for the internaliza-
tion process and no other relevant determinants are contained in 
the last 28 aa of ADAM10 tail.
To confirm the involvement of clathrin-dependent endocytosis in 
ADAM10 internalization, we performed the experiment in the pres-
ence of the dynamin inhibitor dynasore (80 μM for 30 minutes before 
the internalization assay). As shown in Figure 3, A and B, dynasore 
treatment led to a subtle but significant reduction of the TacAD-
AM10-RAR internalization index to the same extent as that of the 
mutation of the AP2-binding domain, proving that clathrin-depen-
dent endocytosis is responsible for ADAM10 removal from the plas-
ma membrane (Figure 3, A and B; TacADAM10-RAR+Dynasore = 
–13.9% ± 4.5%; P < 0.05, TacADAM10-RAR+Dynasore versus Tac-
ADAM10-RAR). As expected, at 4°C there was no internalization 
(Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI65401DS1).
To test whether the lack of the AP2-binding motif and the conse-
quent decrease of internalization rate affected ADAM10 membrane 
levels, ADAM10 WT or ADAM10 AQA was transfected in COS7 cells 
Figure 6
LTD promotes ADAM10 insertion into the membranes, whereas LTP reduces ADAM10 membrane levels. (A) Immunoblot of ADAM10, GluR1-
P845, GluR1, and actin from control and cLTD/cLTP-treated hippocampal cultures either exposed or not exposed to the crosslinker BS3. cLTD 
leads to a significant decrease in ADAM10 intracellular pool, which reflects an augment in ADAM10 surface expression. cLTP significantly increas-
es ADAM10 intracellular pool because cLTP results in a decrease in ADAM10 membrane localization. As expected, cLTD induction reduces and 
cLTP increases the Ser-845 phosphorylation of GluR1. (B) Quantification of the ADAM10/Actin OD ratio of BS3-treated neurons of experiments 
in A (*P < 0.05 cLTD versus C, n = 7, cLTP versus C, n = 3). (C) After either cLTD or cLTP induction, hippocampal cultures were biotinylated and 
the extracts were precipitated with neutravidin. To avoid saturation of band signal in order to carry out precise quantitative analyses, samples of 
extracts (Tot) and neutravidin-precipitated samples (Pp) were loaded such that each lane represents a percentage of the total material per plate. 
Representative immunoblot of ADAM10 and GluR1 from control and treated cultures. (D) ADAM10 OD in Pp samples (surface) was measured 
and normalized to ADAM10 OD in tot samples (total) to calculate the surface/total ratio. Quantification of the surface/total ratio of experiments in C 
(*P < 0.05 cLTD versus C, n = 5, cLTP versus C, n = 6).
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and their surface expression was analyzed by immunofluorescence. 
Both ADAM10 WT and ADAM10 AQA showed a similar 
intracellular pattern staining. The mutant ADAM10 AQA dis-
played stronger surface labeling (Figure 3, C and D; ADAM10 
WT = 1.16 ± 0.17; ADAM10 AQA = 5.56 ± 0.58; P = 4.7 × 10–9, 
ADAM10 WT versus ADAM10 AQA).
Since it has been demonstrated that ADAM10 endocytosis affects 
the ectodomain shedding of ADAM10 itself (37), we checked the 
ectodomain shedding of the AP2-binding–deficient ADAM10 
mutant. In agreement with previous studies (38, 39), we observed 
a fragment of approximately 16 kDa (ADAM10 CTF) in cell lysates 
from HEK293 cells transfected with ADAM10 WT and ADAM10 
AQA. However, in our experimental system, no differences in the 
ADAM10 CTF levels were detected (Supplemental Figure 1B; 
ADAM10 WT, ADAM10 CTF/ADAM10 = 0.62 ± 0.14; ADAM10 
AQA, ADAM10 CTF/ADAM10 = 0.38 ± 0.05; P > 0.05, ADAM10 
WT versus ADAM10 AQA). These experiments demonstrate that 
the AP2-binding motif within ADAM10 Ct controls ADAM10 
endocytosis and plays a role in limiting its surface expression.
The C-terminal tail is therefore the domain responsible for the 
regulation of ADAM10 binding to its intracellular partners, i.e., 
AP2 and SAP97, and these interactions modulate ADAM10 mem-
brane levels and are altered in AD patients’ hippocampus (ref. 15 
and see Figure 1, B and C). In light of these considerations and to 
verify whether genetic modulation of protein/protein interaction 
might occur, screening of ADAM10 C-terminal tail was carried out. 
A sample of 200 patients with possible AD (mean age = 68.0 ± 7.2 yr, 
67.7% female) was screened for ADAM10 exon 15 and exon 16 genet-
ic polymorphisms. In the examined 400 alleles, no genetic variations 
were found. Despite the importance of ADAM10 C-terminal tail, no 
genetic variations associated with AD have been found, suggesting 
that other cellular mechanisms might be responsible for the altered 
interactions between ADAM10 and its partners in AD patients.
Structural characterization of ADAM10/AP2 interaction. As demon-
strated by the results obtained through the analysis of the ADAM10 
mutants (Figure 2), the region of ADAM10 important for the interac-
tion with AP2 contains 2 positively charged residues, R735 and R737, 
and a hydrophilic amino acid, Q736, crucial for binding (Figure 4A). A 
database search for similar sequences in the Protein Data Bank (PDB) 
(40) identified a peptide with a similar sequence (PLPPRNRPRL; Fig-
ure 4A) cocrystallized with the c-Src SH3 domain and derived from a 
phage display library experiment (PDB Id 1QWE) (41). This peptide 
does not have a regular secondary structure, and the side chains of its 
R735 and R737 residues (numbering as in the PDB entry) are oriented 
in opposite direction with respect to N736 (Figure 4B). The analysis 
of the structure of the c-Src SH3-peptide complex shows that the 2 
arginines interact through electrostatic interactions with D23 and 
E39 of its cognate protein, while N736 establishes a hydrogen bond 
with G40 (Figure 4, C and D). The 2 conserved prolines, P733 and 
P734, establish hydrophobic contacts with W42 (Figure 4, C and D).
Figure 7
LTD induces ADAM10 trafficking toward the postsynaptic membranes. (A) WB analysis of homogenate and TIF from control or cLTD-treated 
hippocampal cultures. cLTD leads to a redistribution of SAP97 and ADAM10 in TIF but not in homogenate and to a decrease in Ser-845 phos-
phorylation of GluR1. ADAM22 localization is not affected. (B) Quantification of the ratio of ADAM10/tubulin and SAP97/tubulin OD of experiments 
in A (*P < 0.05, cLTD versus C, n = 4). (C) WB of homogenate and TIF from control and cLTP-treated cultures. Ser-845 phosphorylation of GluR1 
is enhanced, whereas ADAM10, SAP97, and ADAM22 protein levels and localization are not affected. (D) LTD was induced by LFS and TIF was 
purified from CA1 region. WB shows an increased localization of ADAM10 and SAP97 in TIF, while total protein levels are not changed. (E) Quanti-
fication of the ratio of ADAM10/tubulin and SAP97/tubulin OD of experiments in D (*P < 0.05, LTD versus C, n = 4). (F) WB analysis of homogenate 
and TIF from CA1 region of control and LTP-induced slices shows no changes in ADAM10 and SAP97 synaptic localization and total protein levels.
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Given the high degree of sequence similarity between the peptide 
and the C-terminal region of ADAM10, we can hypothesize a similar 
binding mode in the 2 systems. However, AP2 does not contain a 
SH3 domain nor a region with a structure resembling it (Figure 4C). 
Therefore, we searched the AP2 structure for regions similar to that 
interacting with the peptide in the c-Src SH3 complex. We found that 
the only exposed region with a backbone similar to that of the region 
39–42 of the SH3 protein was the 469–472 stretch of the β2 subunit 
of AP2 (Supplemental Figure 2 and ref. 42) that can be superimposed 
with a root mean square deviation (RMSD) of 1.6 Å (Figure 4E).
We used the relative orientation of the peptide/SH3 interacting 
regions as a template to model the interaction between the ADAM10 
C-terminal tail and the AP2 structure (42). Interestingly, after super-
position, the same pattern of side-chain interactions observed in the 
PDB Id complex could be reconstructed with the ADAM10 residues 
P733, P734, Q736, and R737, interacting with residues F469, G472, 
and E471 of AP2 (Figure 4E). Although there is no acidic residue 
corresponding to D23 in the examined region of AP2, residue D437 
of the β2 subunit is properly positioned to establish an electrostatic 
interaction with R735 (distance between [R735-NHC(NH2)2+] and 
(D437-COO–) = 3.6 Å). In summary, although the fold of the bind-
ing region identified on the β2 subunit of AP2 is different from that 
of the c-Src–SH3 domain, the orientation of the residues potentially 
involved in the binding is conserved, as well as the network of inter-
actions they can establish (Figure 4, E and F).
AP2 complex mediates long-term potentiation–induced ADAM10 internal-
ization. At excitatory synapse, the relative rates of insertion/removal of 
glutamate receptors control synaptic abundance of glutamate recep-
tors and, thereby, are tightly regulated by activity dependent synaptic 
plasticity (43). The major routes to govern synaptic insertion/removal 
processes are forward trafficking mechanisms, which require inter-
actions with specific proteins, and clathrin-mediated endocytosis 
(44–46). In light of this consideration and of the relevance of synap-
tic failure in AD pathogenesis (47), we analyzed the effect of synaptic 
plasticity on ADAM10 binding to its partners, i.e., AP2 and SAP97. 
To this, we chose 2 main paradigms of activity-dependent synaptic 
plasticity, i.e., long-term potentiation (LTP) and LTD.
We induced LTP and LTD in primary hippocampal neuronal cul-
tures using highly validated chemical treatments (48, 49) and ana-
lyzed ADAM10 binding to the AP2 complex and to SAP97, using 
co-IP experiments. Chemical LTD (cLTD) was induced with a 
bath application of NMDA (50 μM for 10 minutes) (48), and neu-
rons were recovered in normal ACSF for 20 minutes (Figure 5A). 
To induce LTP, we used a chemical stimulation protocol with 
forskolin plus rolipram for 16 minutes that results in prolonged 
NMDA receptor-dependent LTP (cLTP) (ref. 49 and Figure 5B).
cLTP induction significantly increased ADAM10 precipitation 
with the α-adaptin and β2-adaptin subunits of AP2 complexes 
without affecting SAP97 binding (Figure 5, C and D; α-adaptin = 
+53.7% ± 19.6%, P = 0.04; β2-adaptin = +61.3% ± 19.6%, P = 0.04; 
SAP97 = +0.3% ± 19.3%, P > 0.05; cLTP versus control). On the con-
trary, cLTD fostered the formation of ADAM10/SAP97 without 
altering the interaction with the α-adaptin and β2-adaptin sub-
units of the AP2 complexes (Figure 5, C and D; SAP97 = +40% ± 7.6%, 
P = 0.013; α-adaptin = +5.3% ± 17.0%, β2-adaptin = +0.5% ± 20.3%, 
P > 0.05; cLTD versus control).
To confirm these results, LTP and LTD were induced in 
hippocampal slices by electrophysiological stimulation: LTD was 
induced with low frequency stimulation (LFS) protocol and LTP by 
means of high frequency stimulation (HFS), and after 30 minutes 
Figure 8
ADAM10/SAP97 interaction is required for LTD-induced ADAM10 trafficking and LTD maintenance. (A) Schematic representation of SAP97, 
ADAM10, and Pro peptide. (B) Primary hippocampal cultures were either exposed or not exposed to either Pro or Ala peptide, and, after 30 min-
utes, they were either left untreated or cLTD treated. ADAM10/SAP97 co-IP assays were carried out from total homogenate. cLTD fosters ADAM10/
SAP97 association, while Pro peptide pretreatment prevents this effect. Ala peptide incubation does not affect cLTD-induced ADAM10 trafficking. 
(C) Quantification of OD of experiments in B (*P < 0.05 Pro+LTD versus Ala+LTD, #P < 0.05 Pro+LTD versus LTD, n = 4). (D) Immunoblot of TIF 
obtained from above-described treated cultures. cLTD results in a redistribution of ADAM10 into TIF, whereas Pro, but not Ala peptide, preincubation 
prevents this process. SAP97 localization is not affected by peptide incubation. (E) Quantification of OD of experiments in D (ADAM10, *P < 0.05 
Pro+LTD versus Ala+LTD, #P < 0.05 Pro+LTD versus LTD; SAP97, *P < 0.05 Pro+LTD, Ala+LTD, LTD versus C, n = 4).
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the CA1 region was dissected out to perform the IP assays. Quanti-
tative analyses showed a significant increase in ADAM10/AP2 com-
plex levels after LTP induction, while the ADAM10/SAP97 com-
plex was not affected (Figure 5, E and F; α-adaptin = +50.9% ± 4.7%, 
P = 0.008; β2-adaptin = +81% ± 11.7%, P = 0.01; SAP97 = –1% ± 37.2%, 
P > 0.05; LTP versus control). In contrast, LTD induction promot-
ed ADAM10 binding to SAP97 without modifying the ADAM10/
AP2 interaction (Figure 5, E and F; SAP97 = +291% ± 61.6%, 
P = 0.04; α-adaptin = –19.2% ± 26.6%; β2-adaptin = +4.6% ± 8.4%, 
P > 0.05; LTD versus control).
To analyze whether LTP induces AP2-mediated ADAM10 endocy-
tosis, we first quantified the colocalization of ADAM10 and α-adaptin 
after either cLTP or cLTD induction in hippocampal neurons. A 
quantitative analysis of dendritic ADAM10 staining showed a sig-
nificant increase in ADAM10 colocalization with α-adaptin in cLTP-
treated neurons when compared with control cultures (Figure 5, 
G and H; C = 17.0% ± 2.6%, cLTP = 32.5% ± 3.8%; P = 0.003, cLTP 
versus control). No modifications of colocalization of ADAM10 and 
α-adaptin were detected after cLTD induction (Figure 5, G and H; 
C = 14.4% ± 2.0%, cLTD = 17.8% ± 2.9%; P > 0.05, cLTD versus control).
We then used direct fluorescence-based “antibody feeding” 
assays to measure ADAM10 internalization (50, 51). Neuronal 
cultures were transfected with TacADAM10-RAR, and the assays 
were carried out as described in Figure 3, A and B.
A significant increase in TacADAM10-RAR internalization was 
observed in cLTP-induced neurons when compared with control 
cultures (Figure 5, I and J; internalization index, C37°C = 49.4 ± 5.1, 
cLTP37°C = 74.9 ± 8.3; P = 0.02, C37°C versus cLTP37°C), indicating that 
cLTP promotes TacADAM10-RAR removal from the plasma mem-
brane and increases its intracellular accumulation. No significant 
differences between control and cLTP were observed when traffick-
ing was arrested at 4°C (Supplemental Figure 3) and the internal-
ization index was significantly increased at 37°C compared with 
the 4°C condition (P = 0.003, C4°C versus C37°C; P = 0.0004, cLTP4°C 
versus cLTP37°C), confirming the reliability of our assay. These data 
demonstrate that the AP2 complex is responsible for LTP-induced 
ADAM10 endocytosis, whereas it is not involved in LTD mecha-
nisms, which implicate a modulation of the interaction with SAP97.
LTP and LTD have opposite effects on the plasma membrane expression 
of ADAM10. To demonstrate that ADAM10 endocytosis mediated 
by AP2 could influence ADAM10 membrane levels, we assessed 
ADAM10 surface expression in primary hippocampal cultures by 
biochemical assays after induction of cLTP and cLTD. To carry out 
the crosslinking method (52), control and cLTD hippocampal cul-
tures were treated with the BS3, a membrane-impermeable, irrevers-
ible, amine-reactive crosslinker reagent. The BS3 caused the cross-
linking of surface ADAM10 and the formation of high–molecular 
weight aggregates that barely entered the gel. Therefore, ADAM10 
Figure 9
SAP97-mediated ADAM10 trafficking is necessary for LTD maintenance and LTD-induced spine shrinkage. (A) Time course of the normalized 
fEPSP slope recorded in slices treated with Pro and Ala peptides. Notably, in Pro-treated slices, the LFS protocol fails to induce the LTD, whereas 
in Ala-treated slices, this form of synaptic plasticity is expressed (P < 0.001, Ala n = 13, Pro n = 12). Sample traces of fEPSPs acquired before 
the application of the LFS protocol and 60 minutes after LFS, in Ala-treated slices and in Pro-treated slices. (B) Time course of the normalized 
fEPSP slope recorded in slices treated with Pro and Ala peptides. In both groups, an HFS protocol (arrows) produces a robust LTP. Traces of 
fEPSP acquired before HFS and 60 minutes after HFS indicating a similar fEPSP increase in Ala-treated slices and in Pro-treated slices. (C) 
Primary hippocampal neurons were transfected with GFP construct at DIV7 and, at DIV14, cLTD was induced after incubation with either Ala 
or Pro peptides (1 μm, 30 minutes). Cells were fixed and immunolabeled for GFP. Representative images show dendrites from C, Ala+LTD, and 
Pro+LTD neurons. Scale bar: 5 μm. (D) Diagram showing relative average spine head width (*P < 0.05 Pro+LTD vs. Ala+LTD, Ala+LTD vs. C; 
n > 700 spines from 14 different neurons for each group). (E) Cumulative frequency plots from C, Ala+LTD, Pro+LTD neurons.
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surface pool was not detectable and the modifications of ADAM10 
intracellular pool reflected alterations of ADAM10 surface expres-
sion (12). In cLTD-treated cultures, we observed a significant 
decrease in the ADAM10 intracellular pool (Figure 6, A and B; 
ADAM10 = –27.7% ± 7.1%; P = 0.008, cLTD versus control), indicat-
ing that cLTD promotes ADAM10 insertion in the cell membranes.
As internal control, we measured the surface levels of the AMPA 
receptor subunit GluR1 and its phosphorylation at Ser-845. Phos-
phorylation of Ser-845 by cAMP-dependent PKA (53) regulates the 
surface expression of AMPARs by increasing the pool of GluR1 recy-
cled back to the surface after their endocytosis (17, 46). Surface lev-
els of phosphorylated GluR1 were significantly reduced (Figure 6A; 
GluR1 Ser-845 = –29.7% ± 6.6%; P = 0.045, cLTD versus control), 
while GluR1 surface levels were unchanged probably due to recy-
cling to the plasma membrane (Figure 6A; GluR1 = –9.9% ± 10.6%; 
P > 0.05, cLTD versus control). In fact, when BS3 assays were per-
formed immediately after LTD induction, without recovering neu-
rons, a slight but significant increase of GluR1 intracellular pool 
was detected (GluR1 = +6% ± 1.5%; P = 0.02, cLTD versus control), 
demonstrating GluR1 internalization.
On the other hand, after cLTP induction, a significant increase 
in ADAM10 intracellular pool was detected (Figure 6, A and B; 
ADAM10 = +48% ± 8.4%; P = 0.03, cLTP versus control), indicat-
ing that cLTP triggers ADAM10 removal from the membranes. As 
expected, GluR1 intracellular levels were significantly decreased 
because of membrane insertion (Figure 6A; GluR1 = –19% ± 3.3%; 
P = 0.005, cLTP versus control) and phosphorylation of Ser-845 was 
significantly enhanced (Figure 6A; GluR1 Ser-845 = +66% ± 17.4%; 
P = 0.03, cLTP versus control).
These results were confirmed by surface biotinylation assays. 
Quantitative analyses showed a significant increase in ADAM10 
surface levels in hippocampal cultures after cLTD induction 
(Figure 6, C and D; ADAM10 = +27.3% ± 8.7%; P = 0.035, cLTD 
versus control), whereas cLTP significantly decreased ADAM10 
surface levels (Figure 6, C and D; ADAM10 = –21.5% ± 5.7%; 
P = 0.013, cLTP versus control). As expected, GluR1 membrane 
expression was significantly increased by cLTP (Figure 6C; GluR1 = 
+31% ± 8.2%; P = 0.019, cLTP versus control), while no changes were 
noted after cLTD stimulation (Figure 6C; GluR1 = +25.9% ± 19.6%; 
P > 0.05, cLTP versus control). The efficiency and specificity of 
our assay was verified (Supplemental Figure 4). The precipita-
tion was efficient because no ADAM10 was detected after a sec-
ond precipitation. Moreover, virtually no actin was revealed in 
the neutravidin-precipitated material, indicating that only cell 
surface proteins were recovered. Taken together, these results 
suggest that activity-dependent synaptic plasticity paradigms 
Figure 10
LTD and LTP modulate APP trafficking and processing. (A) WB analysis of APP in homogenate and TIF from control and either cLTD- or cLTP-
treated hippocampal cultures. cLTP leads to a reduction in APP levels in TIF but not in homogenate. cLTD does not affect APP in both homogenate 
and TIF. (B) Quantification of the ratio of APP/tubulin of experiments in A (*P < 0.05, cLTP versus C, n = 5). (C) LTD enhances whereas LTP 
reduces CTF83/CTF99 ratio in hippocampal neurons. APP CTFs were revealed by immunoblotting with 4G8 antibody. (D) Quantification of 
CTF83/CTF99 ratio OD of experiments in C (*P < 0.05 cLTD versus C, cLTP versus C, n = 3). (E) WB analysis of sAPPα released in 1 hour from 
control and cLTD/cLTP-treated hippocampal neuronal cultures. cLTD increases while cLTP reduces sAPPα secretion in primary hippocampal 
cultures. (F) Quantification of sAPPα OD of experiments in E (*P < 0.05 cLTD versus C, cLTP versus C, n = 3). (G) Incubation with the dynamin 
inhibitor dynasore (80 μM, 30 minutes) prevents the cLTP-induced decrease in CTF83/CTF99 ratio. (H) Quantification of OD of experiments in G 
(*P < 0.05 LTP versus C, #P < 0.05 Dynasore+LTP versus LTP, n = 4). (I) Quantification of sAPPα release in the medium of hippocampal neurons 
either exposed or not exposed to either Pro or Ala peptide; after 30 minutes, cLTD was induced. After 20 minutes of recovering, the medium was 
collected and sAPPα levels measured by ELISA assay (*P < 0.05 Pro+LTD versus Ala+LTD, #P < 0.05 LTD versus C, n = 5).
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have an opposite effect on ADAM10 membrane expression: LTP 
induces ADAM10 removal whereas LTD promotes ADAM10 
membrane insertion.
LTD but not LTP stimulates ADAM10 forward trafficking. Since 
ADAM10 is located at the glutamatergic PSDs (12), we asked 
whether activity-dependent synaptic plasticity modulates ADAM10 
synaptic availability. To test this, synaptic Triton insoluble fraction 
(TIF, a fraction highly enriched in all categories of PSD proteins 
and absent of presynaptic markers; ref. 54) was purified from con-
trol and either cLTD- or cLTP-treated neurons, and protein levels 
were measured by Western blot (WB). cLTD stimulation caused 
a significant increase in both ADAM10 and SAP97 levels in TIF 
(Figure 7, A and B; ADAM10 = +28.5% ± 6.0%, P = 0.018; SAP97 = 
+24.8%± 7.7%; P = 0.04, cLTD versus control), a reduction in the 
phosphorylation of Ser-845 of GluR1 (Figure 7A; GluR1 Ser-845 = 
–14% ± 2.4%; P = 0.001, cLTD versus control), and no modifications 
of GluR1 synaptic levels (Figure 7A; GluR1 = +14% ± 9%; P > 0.05, 
cLTD versus control). In contrast, cLTP induction led to no signifi-
cant alterations in ADAM10 and SAP97 synaptic levels (Figure 7C; 
ADAM10 = –21% ± 13.3%, SAP97 = –1.75% ± 13.5%; P > 0.05, cLTP 
versus control), but induced phosphorylation of Ser-845 of GluR1 
(Figure 7C; GluR1 Ser-845 = +381.9% ± 37.1%; P = 0.005, cLTP versus 
control) and increased GluR1 synaptic levels (Figure 7C; GluR1 = 
+43.7% ± 12.0%, P = 0.035, cLTP versus control). No significant 
changes in ADAM10 and SAP97 levels in total homogenate after 
either cLTD or cLTP induction were observed (Figure 7, A and C; 
cLTD, ADAM10 = +37.8% ± 44.3%, SAP97 = +6.5% ± 24.1%; P > 0.05, 
cLTD versus control; cLTP, ADAM10 = –26.8% ± 25%, SAP97 = 
+47.8% ± 26.8%, P > 0.05, cLTP versus control), pointing toward a 
trafficking rather than a transcriptional effect.
To verify the specificity of the effect, we evaluated the postsyn-
aptic levels of ADAM22, another member of the ADAM family 
localized at synapses (55). WB experiments showed no significant 
modifications of ADAM22 levels in total homogenate and TIF 
after either cLTD or cLTP induction (Figure 7, A and C; cLTD, 
ADAM22 = +13.5% ± 18.4%; P > 0.05, cLTD versus control; cLTP, 
ADAM22 = +0.8% ± 11.1%; P > 0.05, cLTP versus control).
Finally, similar results were obtained when LTP and LTD were 
induced in hippocampal slices by electrophysiological stimula-
tion, providing further validation of our results. Thirty minutes 
after LTD induction, the TIF was purified from the CA1 region of 
hippocampal slices and quantitative WB analyses showed a signifi-
cant increase in both ADAM10 and SAP97 levels after 30 minutes 
(Figure 7, D and E; ADAM10 = +31.0% ± 10.4%, P = 0.03; SAP97 = 
+27.1% ± 10.6%; P = 0.04, LTD versus control). In contrast, LTP 
induction did not change ADAM10 and its binding partner SAP97 
synaptic levels (Figure 7F, ADAM10 = –7.5% ± 19.3%, SAP97 = 
–13.8% ± 13.4%; P > 0.05, LTP versus control). No significant 
alterations of total ADAM10 and SAP97 levels after either LTD or 
LTP induction were detected (Figure 7, D and F; LTD, ADAM10 = 
+32% ± 28.1%, SAP97 = +11% ± 7.6%, P > 0.05, LTD versus control; 
LTP, ADAM10 = –22% ± 13.3%, SAP97 = +3% ± 15%, P > 0.05, LTP 
versus control). These results indicated that LTD, but not LTP, 
increases ADAM10 membrane expression by stimulating SAP97-
mediated ADAM10 trafficking, revealing that activity-dependent 
plasticity exerts a bidirectional control of ADAM10 synaptic levels 
in the postsynaptic compartment.
SAP97-mediated LTD-induced ADAM10 trafficking is required for 
LTD. To clarify the role of SAP97 in LTD-induced ADAM10 traf-
ficking, we took advantage of the cell-penetrating Pro peptide to 
disrupt the ADAM10/SAP97 interaction (Figure 8A and ref. 12). 
Treatments with Ala peptide were always performed as control. 
Hippocampal cultures exposed or not exposed to either Pro or Ala 
peptide (1 μM, 30 minutes) were then treated with NMDA (50 μm, 
10 minutes) to induce cLTD.
To test the efficacy of the treatment, cells were lysed after 20 min-
utes of recovering, and co-IP assays were performed. As shown in 
Figure 5C, cLTD induction stimulates ADAM10/SAP97 complex 
formation, significantly raising ADAM10/SAP97 co-IP (Figure 8, B 
and C; LTD = +34.3% ± 9.6%; P < 0.05, LTD versus control). Prein-
cubation with the Pro peptide prevented this effect (Figure 8, B and 
C; Pro+LTD = –10.8% ± 6.5%; P < 0.05 Pro+LTD versus Ala+LTD, 
Pro+LTD versus LTD), thus proving this strategy useful for verify-
ing the role of SAP97 in LTD-induced ADAM10 trafficking to the 
postsynaptic membrane. Treatment with the control Ala peptide 
did not affect LTD-induced ADAM10/SAP97 association (Figure 8, 
B and C; Ala+LTD = +38.5% ± 7.7%; P > 0.05, Ala+LTD versus LTD).
To analyze ADAM10 and SAP97 localization, we purified the 
PSD protein-enriched TIF from neuronal cultures exposed or 
not exposed to either Pro or Ala peptide and then treated with 
NMDA (50 μm, 10 minutes). As previously shown (Figure 7, A 
and B), quantification of ADAM10 staining revealed a significant 
increase in both ADAM10 and SAP97 levels in synaptic mem-
branes after cLTD induction (Figure 8, D and E; LTD, ADAM10 = 
+41% ± 9.5%, SAP97 = +31% ± 9.8%; P < 0.05, LTD versus control). 
Conversely, when neuronal cultures were preincubated with Pro, 
cLTD failed to induce the increase in ADAM10 localization at the 
synapse, whereas SAP97 levels were not affected (Figure 8, D and E; 
Pro+LTD, ADAM10 = –4.3% ± 6.1%, SAP97 = +34% ± 7.1%; P < 0.05, 
Pro+LTD versus Ala+LTD, Pro+LTD versus LTD). No effect was 
induced by treatment with the Ala control peptide on ADAM10 
and SAP97 localization (Figure 8, D and E; Ala+LTD, ADAM10 = 
+33.3 5 ± 6.8%, SAP97 = +46.3% ± 6.8%; P > 0.05, Ala+LTD versus 
LTD). Hence, the cell-permeable peptide, which interferes with 
ADAM10/SAP97 association, is able to prevent cLTD-induced 
ADAM10 trafficking to the postsynaptic compartment, indicating 
the pivotal role of SAP97 in LTD-induced ADAM10 trafficking.
Since LTD is bearing ADAM10 to the postsynaptic compartment, 
we attempted to determining whether the hampering of ADAM10 
trafficking occludes LTD. Hippocampal slices were incubated for 
30 minutes with either Pro or Ala peptide before recording field excit-
atory postsynaptic potentials (fEPSPs) in CA1 region and inducing 
LTP or LTD. As shown in Figure 9A, treatment with the Pro peptide 
was sufficient to abolish the maintenance of LTD induced by LFS 
(P < 0.001, Pro versus Ala). On the contrary, we found that exposure 
of hippocampal slices to the Pro peptide had no detectable effect on 
the ability to elicit robust LTP by HFS when compared with slices 
treated with Ala control peptide (Figure 9B, P > 0.05 Pro versus Ala). 
No effect of the Pro peptide on baseline transmission was observed. 
The specificity and efficacy of the peptide has been proven as previ-
ously described (12, 13, 16) and as shown in Supplemental Figure 5.
These results indicate that SAP97-mediated ADAM10 traffick-
ing is required for hippocampal LTD expression. LTD is associated 
with a marked shrinkage of the spine head (56, 57), but the cellu-
lar mechanisms underlying this event are still not completely clear. 
Since we have previously demonstrated ADAM10 cleavage activity 
role in spine remodeling (13), we tested whether ADAM10 could be 
involved in LTD-induced spine morphology changes.
GFP-transfected hippocampal neurons were incubated with 
either Pro or Ala peptide (1 μM, 30 minutes), and then cLTD was 
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Since SAP97 is responsible for LTD-induced ADAM10 delivery 
to the postsynaptic compartment, we determined whether the 
treatment with Pro peptide was able to affect LTD-induced sAPPα 
release. Hippocampal cultures exposed or not exposed to either 
Pro or Ala peptide (1 μM, 30 minutes) were then treated with 
NMDA (50 μm, 10 minutes) to induce cLTD. The medium was 
collected after 20 minutes of recovering, and the amount of sAPPα 
released was measured by ELISA assays. As shown in Figure 10I, 
the treatment with Pro peptide prevented the LTD-induced 
marked increase in sAPPα release, whereas the control peptide 
Ala had no effect (Figure 10I, LTD = +113.7% ± 26.1%, Ala+LTD = 
+80.2% ± 17%, Pro+LTD = –5.2% ±27.5%, P < 0.05, LTD versus 
control, Pro+LTD versus Ala+LTD, Pro+LTD versus LTD). Over-
all, these data suggest that activity-dependent synaptic plasticity 
exerts a bidirectional effect on APP shedding through the modula-
tion of ADAM10 endocytosis/trafficking.
Discussion
Several studies highlighted the key role of the disintegrin and 
metalloproteinase family member ADAM10 in health and dis-
ease, due to its shedding activity toward a number of functional 
membrane proteins such as APP and N-cadherin (13, 60). In fact, 
through its shedding activity, ADAM10 has been shown to regulate 
key cellular functions including cell growth, adhesion, and migra-
tion and spine stabilization in excitatory neurons (13, 61, 62).
Hence, a finely balanced membrane level of ADAM10 is an essen-
tial prerequisite to control enzyme activity and its functions (63). A 
possible approach to modulating enzyme membrane availability can 
be to interfere with mechanisms regulating its intracellular traffick-
ing. In this context, ADAM10 protein interactors regulating its for-
ward trafficking have been previously characterized (12, 64). Less is 
known about mechanisms regulating ADAM10 membrane retrieval, 
although a balance between these 2 processes may represent another 
way to influence ADAM10 strength and shedding activity.
Here, we report that ADAM10 removal from the plasma mem-
brane is mediated by clathrin-dependent endocytosis and represents 
what we believe is a novel mechanism to finely tune its synaptic 
availability. The clathrin adaptor AP2, a heterotetrameric assem-
bly that initiates the endocytosis process, directly interacts with 
ADAM10 C-terminal domain. Here, we describe a pathological role 
of the ADAM10/AP2 complex in AD patients and a physiological 
role of the same complex in activity-dependent synaptic plasticity. 
In particular, in addition to a defect in ADAM10 binding to SAP97 
(15), we report the concomitant increase in ADAM10 association to 
the clathrin adaptor AP2 in the hippocampus of AD patients.
Our results suggest that in early stages of the disease, the reduc-
tion of α-secretase activity (15) could be ascribed to a defect in 
ADAM10 exocytosis/endocytosis processes rather than to an altera-
tion of its expression. Furthermore, this alteration is not related 
to the presence of genetic variations in the C-teminal domain of 
ADAM10. Indeed, modifications of endo/exocytosis mechanisms 
in AD have been put forward by several observations. First, GWAS 
studies have identified a number of genes coding for endocytic fac-
tors, such as PICALM, as susceptibility loci for sporadic AD (23–25). 
Second, neurons obtained by reprogramming AD patients’ fibro-
blasts have early endosome phenotypes (65). Third, Aβ oligomers 
have been reported to affect clathrin-dependent endocytosis (26).
These studies pointed to a role of endocytic mechanisms in AD 
pathogenesis primarily focusing on the presynaptic site, i.e., syn-
aptic vesicles release, APP recycling mechanisms (26). Our findings 
induced by NMDA bath (50 μM, 10 minutes). After 20 minutes 
of recovering, cells were fixed and immunolabeled with an anti-
GFP antibody; average spine head width and number of dendritic 
spines were evaluated. Statistical analysis revealed a significant 
decrease in spine head width in the Ala+LTD-treated neurons 
when compared with the controls (Figure 9, C and D; Ala+LTD = 
–13.2% ± 2.3%; P < 0.05, Ala+LTD versus control). On the other 
hand, in neurons incubated with the Pro peptide, LTD induc-
tion did not lead to a reduction of spine head width (Figure 9, C 
and D; Pro+LTD = –0.1% ± 2.2%; P > 0.05, Pro+LTD versus con-
trol, Pro+LTD versus Ala+LTD), demonstrating the relevance of 
ADAM10 for LTD-induced spine shrinkage. Cumulative frequen-
cy plots of spine head width confirmed a significant shift toward 
smaller spine size in Ala+LTD-treated neurons that was rescued 
by preincubation with the Pro peptide (Figure 9E). No significant 
changes in the mean spine density were found (C = 3.85 ± 0.33 
spines/10 μm, Ala+LTD = 3.58 ± 0.20 spines/10 μm, Pro+LTD = 
3.64 ± 0.27 spines/10 μm, P > 0.05).
Activity-dependent synaptic plasticity modulates APP shedding. Syn-
aptic activity has been shown to regulate APP-processing, leading 
to alterations in Aβ production (58). Therefore, we determined 
whether activity-dependent synaptic plasticity could affect APP 
trafficking and processing.
First of all, we analyzed APP total and synaptic levels after either 
cLTD or cLTP induction in hippocampal cultures. As shown in 
Figure 10A, cLTP significantly reduced APP synaptic localization, 
as previously reported (59), while cLTD did not modify APP levels 
in the TIF (Figure 10, A and B; LTP = –44.2% ± 13%, P = 0.027, LTP 
versus control; LTD = –0.5% ± 13%, P > 0.05, LTD versus control). 
Since ADAM10 synaptic levels are modulated by activity-depen-
dent synaptic plasticity (Figures 5 and 6) and the enzyme is active 
toward its substrates when localized at the plasma membrane (9), 
we determined whether the shedding of APP was affected by activ-
ity-dependent synaptic plasticity.
APP-processing products were further investigated in 
hippocampal neuronal cultures after either cLTD or cLTP 
induction. In these experimental conditions, both sAPPα 
release in the medium and APP CTFs — CTF99 (for BACE-
cleavage) and CTF83 (for ADAM10 cleavage) — were evalu-
ated in the TIF. In neuronal cultures, the CTF83/CTF99 
ratio was significantly increased by cLTD and decreased after 
cLTP induction (Figure 10, C and D; cLTD, CTF83/CTF99 = 
+13.1% ± 1.0%, P = 0.006, cLTD versus control; cLTP, CTF83/
CTF99 = –13.0% ± 3.8%, P = 0.04, cLTP versus control), sug-
gesting that LTD enhances while LTP reduces ADAM10 activity 
modulating APP metabolism.
As further proof of these results, we detected a significant 
increase in sAPPα release in the neuronal medium collected after 
1 hour recovery from cLTD induction (Figure 10, E and F; LTD = 
+309% ± 38.4%, P = 0.02, LTD versus control). In contrast, LTP 
causes a significant reduction in sAPPα release (Figure 10, E and F; 
LTP = –42% ± 6.2%, P = 0.02, LTP versus control).
To prove the involvement of ADAM10 endocytosis in the shift-
ing of APP processing toward amyloidogenesis, we took advantage 
of the dynamin inhibitor dynasore, which interferes with ADAM10 
endocytosis as shown in Figure 3, A and B. In neuronal cultures 
preincubated with dynasore, cLTP did not lead to the expected 
decrease in the CTF83/CTF99 ratio (Figure 10, G and H; LTP = 
–33.2% ± 9.9%, dynasore+LTP = +9.7% ± 5.8%, P < 0.05 LTP versus 
control, LTP versus dynasore+LTP).
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ulates ADAM10 cleavage of APP. It has been reported that neuronal 
activity dynamically influences Aβ levels in vivo (66) and modulates 
APP processing at the β-secretase site (58). Our data demonstrate 
that neuronal activity, and in particular, activity-dependent synap-
tic plasticity, also affects ADAM10 activity and, thereby, modulates 
APP processing. Moreover, interfering with the mechanisms under-
lying ADAM10 trafficking/endocytosis prevents the modulation of 
APP processing triggered by activity-dependent synaptic plasticity. 
Regulated interaction of ADAM10 with SAP97 and AP2 discloses 
a physiological mechanism of ADAM10 activity regulation at the 
synapses. This phenomenon produces a situation whereby synapti-
cally regulated ADAM10 activity is positioned to modulate synaptic 
functioning. The balance between these 2 partners’ association is 
impaired in AD patients’ hippocampus at early stages of disease, 
leading to a reduction of ADAM10 levels at the postsynaptic com-
partment (15). In light of the role of ADAM10 in Aβ production and 
synapse function, this loss of balance could affect both APP process-
ing and activity-dependent synaptic plasticity in AD.
Together, these results put forward an innovative and compre-
hensive vision of AD pathogenesis recapitulating the amyloid 
cascade in the synaptic context and taking into account the strict 
interdependence of amyloid cascade and synaptic activity.
Methods
Human studies. Hippocampi from 6 AD patients and 6 HC were obtained 
from the Netherlands Brain Bank (NBB). Established Braak and Braak cri-
teria were used to categorize AD tissues (29). AD patients fulfilled Braak 
4 stage. Accordingly, in AD cases, there were tangles and neuritic plaques 
in hippocampus. HC had no history of psychiatric or neurological disease 
and no evidence of age-related neurodegeneration.
Genetic sequencing of ADAM10 Ct. Patients were consecutively enrolled 
from a tertiary referral centre for memory disturbances, University of 
Brescia, and fulfilled current clinical criteria for AD. Total genomic DNA 
was prepared from peripheral blood according to standard procedures. 
Exon 15 and exon 16 of ADAM10 and at least 30 bp of their flanking 
introns were evaluated by PCR. Primers were designed for exon 15 (F:5′-
CAGTGGAAAAATCTGTTTATTT-3′, R:5′-TATAATTCAATTCTACCTGC-
TAAA-3′) and exon 16 (F:5′-TTTCTTATTGAAACAGCAGCTTTGC-3′, 
R:5′-CTCTTTGGAGTGAAGTTTTCCCAT -3′). PCR annealing tempera-
tures were 51°C and 58°C, respectively. The PCR products were separated 
on a 2% agarose gel, and the fragments were evaluated by denaturing HPLC 
(dHPLC) analysis (Transgenomic).
Neuronal culture treatment, TIF preparation, crosslinking assay. To induce chem-
ical LTP, hippocampal neuronal cultures at 14 DIV were first incubated in 
artificial cerebrospinal fluid (ACSF) for 30 minutes: 125 mM NaCl, 2.5 mM 
KCl, 1 mM MgCl2, 2 mM CaCl2, 33 mM D-glucose, and 25 mM HEPES (pH 7.3; 
320 mosM final), followed by stimulation with 50 μM forskolin, 0.1 μM rolip-
ram, and 100 μM picrotoxin (Tocris) in ACSF (no MgCl2). After 16 minutes 
of stimulation, neurons were replaced in regular ACSF for 15 minutes and 
then subjected to TIF extraction or surface-expression assays (48, 49). To 
induce cLTD, neuronal cultures were incubated in ACSF for 30 minutes, 
followed by stimulation with 50 μM NMDA (Sigma-Aldrich) in ACSF. After 
10 minutes of stimulation, neurons were replaced in regular ACSF for 20 minutes 
and then subjected to TIF extraction or surface-expression assays (48, 49). 
TIF was isolated from either neurons or acute hippocampal slices as pre-
viously described (54). Crosslinking experiments by means of BS3 (Pierce) 
were performed as previously described (12, 52, 67).
Surface biotinylation. Hippocampal cultures were washed once with PBS/
Ca2+/Mg2+ (10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl, 1 mM 
CaCl2, 0.5 mM MgCl2, pH 7.4) at 37°C and then cooled gradually to 4°C 
highlight the importance of exo/endocytosis mechanisms also in 
the postsynaptic compartment.
The structural determinants of ADAM10/AP2 interaction have 
been defined in minute details using several approaches. In particular, 
we have identified an atypical AP2-binding motif in ADAM10 Ct: the 
735RQR737 sequence is necessary for AP2 binding and ADAM10 inter-
nalization. The lack of AP2 interaction significantly affects ADAM10 
plasma membrane levels, underlining the relevance of clathrin-medi-
ated endocytosis in the modulation of ADAM10 surface expression.
Moreover, we carried out a careful mapping of the ADAM10 
tail, demonstrating that the domains responsible for the interac-
tion with AP2 complex and SAP97 do not overlap. The last 15-aa 
sequence, containing the 735RQR737 motif, is responsible for the 
binding to AP2 complex, while SAP97, previously reported to bind 
the 2 proline-rich domains of ADAM10 tail (12), mainly interacts 
with the most membrane-proximal proline-rich domain and the 
second proline stretch is not essential.
We also propose a physical model for the interaction between 
the tail region of ADAM10 and AP2 based on structural similarity 
with a known protein-peptide complex. Clearly the hypothesized 
mode of interaction is only speculative; we present it here as it can 
be used as a guide for site directed mutagenesis experiment.
Furthermore, we demonstrate that SAP97 and clathrin adaptor 
AP2 are critical links between activity-dependent synaptic plas-
ticity and ADAM10. In particular, here we show that the 2 main 
paradigms of activity-dependent synaptic plasticity, i.e., LTP and 
LTD, have opposite effects on ADAM10 association to its binding 
partners, i.e., SAP97 and AP2, thus affecting ADAM10 localization 
and activity in hippocampal neurons.
It turned out that ADAM10 undergoes a dynamic regulation of 
its membrane levels by activity-dependent synaptic plasticity: LTD 
boosts ADAM10 membrane insertion by fostering its SAP97-medi-
ated forward trafficking to synaptic membrane, whereas LTP reduces 
the enzyme membrane levels by inducing AP2-mediated endocytosis.
We then asked why ADAM10 surface expression is finely tuned 
by activity-dependent synaptic plasticity. We demonstrate that 
SAP97-mediated ADAM10 forward trafficking represents a process 
necessary for LTD expression. LTD induction enhances ADAM10/
SAP97 complex formation. This interaction is necessary for LTD-
induced ADAM10 trafficking, since the treatment of hippocampal 
neurons with the cell-permeable Pro peptide mimicking the pro-
line-rich region of ADAM10 and disrupting SAP97/ADAM10 inter-
action counteracts the capability of LTD to foster SAP97/ADAM10 
complex to the membrane. Besides interfering with LTD-induced 
ADAM10 trafficking, the uncoupling of ADAM10 and SAP97 also 
hampers LTD maintenance and LTD-induced spine shrinkage.
In light of the above, ADAM10 delivery to the postsynaptic 
compartment seems to be critical for synaptic activity–induced 
spine remodeling. In fact, ADAM10 cleavage of synaptic adhe-
sion molecules may allow the activated synapse to rapidly mod-
ulate the spine size during induction of activity-dependent syn-
aptic plasticity (13, 14).
Activity-dependent synaptic plasticity also represents an impor-
tant mechanism of regulation of ADAM10 activity toward APP at 
synaptic membranes. According to previous studies (59), APP synap-
tic levels are reduced by LTP, whereas LTD does not affect its local-
ization at the postsynaptic compartment. The measurement of both 
sAPPα release and of the levels of APP CTFs — CTF99 for BACE 
cleavage and CTF83 for ADAM10 cleavage — in the postsynaptic 
compartment demonstrated that LTP decreases whereas LTD stim-
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analysis was performed using AIM 4.2 software (Zeiss). For quantification 
of internalization, all images were analyzed using ImageJ, the average fluo-
rescence intensities in the green (total) and red (internalized) channels were 
measured, background subtracted, and the internalized/fluorescence ratio 
was calculated for each cell. The average intensity of surface fluorescence 
staining (red) was determined after cell tracing and normalized to the total 
intensity (green) to correct for differences in expression. Surface ratios were 
obtained by dividing the background subtracted fluorescence intensities. 
Morphological analysis was performed with ImageJ software to measure 
spine head width. For electrophysiological experiments, data are presented 
as means ± SEM. LTP or LTD value was calculated for each single experiment 
as the percentage of increase in the slope of the fEPSP during minutes 55 to 
60 after the end of HFS or LFS, respectively, compared with control baseline.
Statistics. Statistical evaluations were performed by using 2-tailed Stu-
dent’s t test (a P value less than 0.05 was considered significant.) or, when 
appropriate, by using 1-way ANOVA followed by Bonferroni’s post hoc test.
Study approval. All experimental procedures were carried on with care to 
minimize discomfort and pain to treated animals in accordance with the 
guidelines of the European Communities Council (Directive of Novem-
ber 24, 1986, 86/609/EEC) and were approved by the Italian Ministry of 
Health (as indicated in Digs n. 295/2012-A). For the experiments carried 
on human brain samples, all procedures were in accordance with the NIH 
Guide for Care and Use of Laboratory Human Tissues and were approved 
by the Ethics Committee of the University of Milan. For the genetic analy-
sis, written informed consent (from the subject or from the responsible 
guardian if the subject was incapable) was obtained, before study initia-
tion, for blood collection and genotyping. The work conformed with the 
Declaration of Helsinki and was approved by the local Ethics Committee.
See Supplemental Methods for details on antibodies and cell-permeable 
peptide, DNA constructs, acute hippocampal slices, cell cultures and trans-
fection methods, SDS-PAGE, determination of sAPPα release, IP experi-
ments, GST -fusion protein production and pulldown assay, immunocy-
tochemistry and colocalization analysis, and structural characterization.
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before they were washed twice with cold PBS/Ca2+/Mg2+. Cultures were 
incubated with biotinylation reagent (1.5 mg/ml NHS-SS-biotin [Pierce]
in PBS/ Ca2+/Mg2+) at 4°C for 20 minutes, and then washed 3 times with 
cold PBS/Ca2+/Mg2+ including 50 mM glycine. Cells were scraped into cold 
lysis buffer, and total membrane fraction (Tot) was extracted and mixed 
with UltraLink immobilized neutravidin beads (Pierce) and rotated for 
2 hours at 4°C. The beads were washed 5 times, and after the addition of 
SDS-PAGE sample buffer to the beads, the resulting slurry (Pp) was boiled 
for 3 minutes. To evaluate the efficiency of the biotinylation reaction, 
the first supernatant was reprecipitated with neutravidin beads, and the 
additional neutravidin-precipitated material was loaded as well (Pp2) (68). 
Proteins were resolved by SDS-PAGE and probed with the anti-ADAM10, 
anti-GluR1 or anti-actin antibodies. To avoid saturation of band signal in 
order to carry out precise quantitative analyses, samples of Tot and Pp were 
loaded such that each lane represented a percentage of the total material 
per plate. Proteins were visualized with ECL (GE Healthcare).
Internalization assays. To label surface TacADAM10-RAR, TacADAM10-
RAR AQA, and Tac ADAM10 721Δ, live COS7 cells were incubated with 
anti-Tac antibody for 45 minutes in medium at 4°C, while live neurons 
were labeled by incubation in ACSF with anti-Tac antibody for 30 minutes 
at 10°C. After brief washing in DMEM, COS7 cells were returned to 37°C 
for 10 minutes. Neurons were washed with cold ACSF, and internaliza-
tion was allowed at 37°C in response to cLTP induction (16 minutes plus 
15 minutes to allow internalization). A parallel set of controls was kept 
at 4–8°C to stop trafficking. Cells were then fixed with 4% PFA and 4% 
sucrose in PBS, pH 7.4 and blocked with normal serum; remaining surface 
Tac chimeras were labeled with 488 secondary antibody (nonpermeabi-
lized), and internalized receptors were labeled with 555-conjugated second-
ary antibody after Triton permeabilization. In some experiments, dynasore 
(80 μM; Tocris Bioscience) was added for 30 minutes to block receptor 
internalization. For COS7 internalization experiments, wide-field fluo-
rescence images were acquired with a Zeiss ×40 objective and a CoolSnap 
CCD camera. For neurons, fluorescence images were acquired by using the 
confocal LSM510 Meta system (Zeiss) with a ×63 objective and a sequential 
acquisition setting at 1024 × 1024 pixel resolution; for each image, 2 to 3 
sections of 0.5 μm were acquired, and z-projection was obtained.
Electrophysiological experiments. Acute hippocampal slices (400 μm) were 
placed into an interface recording chamber where they were continuously 
perfused with oxygenated ACSF maintained at 29°C and at a flowing rate 
of 1.6–1.8 ml/min. Extracellular fEPSPs were recorded in stratum radiatum 
of CA1 with glass electrodes filled with 3 M NaCl coupled to the input 
stage of a Warner IE-210 amplifier as previously described (16). Briefly, 
stimuli were delivered to the Schaffer collateral/commissural afferents 
with bipolar concentric stainless steel electrodes. Basal stimulation fre-
quency was 0.1 Hz. LTP was induced by a HFS protocol: 4 trains of 100 Hz 
for 1 second, separated by 30 seconds LTD was induced by delivering an 
LFS protocol: 600 pulses at 1 Hz. The slope of the rising phase of the fEPSP 
was calculated as a measure of the synaptic response.
Data analysis. Quantification of WB analysis was performed by means of 
computer-assisted imaging (ImageJ) after normalization on tubulin or actin 
levels, and values were expressed as mean ± SEM. For internalization or sur-
face/total ratio assays, colocalization, and morphological analysis, cells were 
chosen randomly for quantification from 4 different coverslips (2 indepen-
dent experiments), images were acquired using the same settings/exposure 
times, and at least 10 cells for each condition were analyzed. Colocalization 
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